Stock Financial Ratios


MRTX / Mirati Therapeutics, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price18.25
Volume307,600.00
Market Cap ($M)430.75
Enterprise Value ($M)211.56
Book Value ($M)48.31
Book Value / Share2.44
Price / Book6.32
NCAV ($M)48.44
NCAV / Share2.45
Price / NCAV6.65
Income Statement (mra) ($M)
Revenue0.00
EBITDA-83.78
Net Income-83.12
Balance Sheet (mrq) ($M)
Cash & Equivalents20.78
Cash / Share1.05
Assets82.06
Liabilities13.58
Quick Ratio3.97
Current Ratio3.97
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-1.72
Return on Assets (ROA)-1.31
Return on Equity (ROE)-1.72
Identifiers and Descriptors
CUSIP60468T105
Central Index Key (CIK)1576263
Industry Groups
SIC 2834 - Pharmaceutical Preparations
Other Related CUSIPS
60468T955
60468T905
Share Statistics
Common Shares Outstanding (M)25.30
Scoring Models
Piotroski F Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Accumulated Depreciation And Depletion Per Share0.04
Inventory Work In Progress Per Share0.00
Assets Per Share4.15
Long Term Debt Per Share0.00
Property Plant And Equipment Per Share0.03
Treasury Stock Per Share0.00
Assets Other Non Current Per Share0.11
Additional Paid In Capital Per Share25.34
Debt Per Share0.00
Assets Current Per Share4.01
Deferred Income Tax Liabilities Per Share0.00
Liabilities Per Share0.69
Cash And Equivalents Per Share1.05
Cash Per Share1.05
Retained Earnings Per Share-22.37
Liabilities Other Non Current Per Share0.00
Intangibles Per Share0.00
Goodwill Per Share0.00
Property Plant And Equipment Net Per Share0.03
Minority Interest Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Property Plant And Equipment Gross Per Share0.07
Accounts Receivable Per Share0.00
Inventory Raw Materials Per Share0.00
Liabilities Current Per Share0.69
Assets Other Current Per Share0.00
Accounts Payable Per Share0.00
Inventory Finished Goods Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Liabilities And Stock Equity Per Share4.15
Inventory Per Share0.00
Equity Per Share3.44

Related News Stories

Albireo Pharma: Updates To Thesis

2017-11-17 seekingalpha
Shares have risen nearly 20% since my initial write-up and I believe the initial bull thesis remains intact. (72-2)

Cramer Remix: Warren Buffett selling IBM could mean IBM's turning

2017-11-16 cnbc
CNBC's Jim Cramer didn't want to be so quick as to write off Thursday's rally to the House of Representatives passing its first iteration of tax reform. (69-0)

Cramer's lightning round: Opko Health is a 'neighborhood of pain'

2017-11-16 cnbc
Opko Health Inc.: "Oh my god, the quarter, not good. I mean, this thing has become a genuine house of pain. No, this is like a neighborhood of pain. And until [CEO] Dr. Frost comes on, we're going to back away. We have to. We have to." (207-1)

Mirati Therapeutics: Buy The Dip

2017-11-15 seekingalpha
At one point shares rose by as much as 45% since my initial article in September. I believe today´s dip represents a buying opportunity. (78-0)

Stellar BioSciences For Value Investors

2017-10-17 seekingalpha
The biotech sector has been red hot with key firms gaining substantial value for investors. Among those companies stands out Spectrum Pharmaceuticals (NASDAQ:SPPI), a firm that focuses on the innovation and commercialization of therapeutics to treat cancers. Since fellow Seeking Alpha, Decision Analytics (“DA”), initiated the buy recommendation on Spectrum, the stock soared by more than 34%. With more than a decade of experience investing in the bioscience sector, DA also authored a number of scientific publications. (272-5)

CUSIP: 60468T105